Literature DB >> 24044360

Standard recommendations for the application of Chinese clinical cell therapy for neurorestoration (2012).

.   

Abstract

Cell therapy has been shown to be a promising alternative therapy for neurorestoration, and more than 30 different types of cells have been shown to possess some capability to restore lost or damaged neurological functions. Chinese physicians have successfully applied cell therapy to many neurological diseases and damages in the clinic and contributed to establish a discipline of neurorestoratology. To standardize the clinical procedures of cell therapy as one of the strategies for treating neurological disorders, the Chinese Branch of the International Association of Neurorestoratology (IANR) and the Preparatory Committee of Chinese Association of Neurorestoratology recently completed the Standard Recommendations (2012) for the Application of Chinese Clinical Cell Therapy for Neurorestoration. We hope these recommendations will guide clinical practice in applying cell therapy for neurorestoration, which will therein offer a reference for both Chinese and other countries' governments to make relevant official regulations. This manuscript is published as part of the International Association of Neurorestoratology (IANR) supplement issue of Cell Transplantation.

Entities:  

Mesh:

Year:  2013        PMID: 24044360     DOI: 10.3727/096368913X672082

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  2 in total

1.  The pluralization of the international: Resistance and alter-standardization in regenerative stem cell medicine.

Authors:  Achim Rosemann; Nattaka Chaisinthop
Journal:  Soc Stud Sci       Date:  2016-02       Impact factor: 3.885

2.  Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017).

Authors:  Hongyun Huang; Wise Young; Lin Chen; Shiqing Feng; Ziad M Al Zoubi; Hari Shanker Sharma; Hooshang Saberi; Gustavo A Moviglia; Xijing He; Dafin F Muresanu; Alok Sharma; Ali Otom; Russell J Andrews; Adeeb Al-Zoubi; Andrey S Bryukhovetskiy; Elena R Chernykh; Krystyna Domańska-Janik; Emad Jafar; W Eustace Johnson; Ying Li; Daqing Li; Zuo Luan; Gengsheng Mao; Ashok K Shetty; Dario Siniscalco; Stephen Skaper; Tiansheng Sun; Yunliang Wang; Lars Wiklund; Qun Xue; Si-Wei You; Zuncheng Zheng; Milan R Dimitrijevic; W S El Masri; Paul R Sanberg; Qunyuan Xu; Guoming Luan; Michael Chopp; Kyoung-Suok Cho; Xin-Fu Zhou; Ping Wu; Kai Liu; Hamid Mobasheri; Seiji Ohtori; Hiroyuki Tanaka; Fabin Han; Yaping Feng; Shaocheng Zhang; Yingjie Lu; Zhicheng Zhang; Yaojian Rao; Zhouping Tang; Haitao Xi; Liang Wu; Shunji Shen; Mengzhou Xue; Guanghong Xiang; Xiaoling Guo; Xiaofeng Yang; Yujun Hao; Yong Hu; Jinfeng Li; Qiang Ao; Bin Wang; Zhiwen Zhang; Ming Lu; Tong Li
Journal:  Cell Transplant       Date:  2018-02       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.